GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmunoPrecise Antibodies Ltd (NAS:IPA) » Definitions » Short Interest

IPA (ImmunoPrecise Antibodies) Short Interest


View and export this data going back to 2011. Start your Free Trial

What is ImmunoPrecise Antibodies Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of ImmunoPrecise Antibodies's Short Interest

For the Biotechnology subindustry, ImmunoPrecise Antibodies's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ImmunoPrecise Antibodies's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ImmunoPrecise Antibodies's Short Interest distribution charts can be found below:

* The bar in red indicates where ImmunoPrecise Antibodies's Short Interest falls into.


;
;

ImmunoPrecise Antibodies Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmunoPrecise Antibodies Ltd (NAS:IPA) » Definitions » Short Interest
Comparable Companies
LPCN IBO EDSA ORGS BIVI PTN NNVC CLDI UBX NEUP VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
TQB:Germany TQB:Germany
Address
3204 - 4464 Markham Street, Victoria, BC, CAN, V8Z 7X8
Website
https://www.ipatherapeutics.com
ImmunoPrecise Antibodies Ltd is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series proprietary and patented technologies. The company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies and are known for solving very complex industry challenges.